Abstract
Nanoparticles have emerged as a transformative tool in the field of cancer therapy, providing a means to deliver drugs and therapeutic agents with enhanced precision and efficiency. These nanoscale carriers can be engineered to target cancer cells specifically, reducing the harmful side effects associated with conventional chemotherapy. Despite their promising potential, the clinical translation of nanoparticles in cancer therapy faces several challenges, including issues related to bioavailability, toxicity, and immune responses. This article explores the role of nanoparticles in cancer therapy, highlighting the challenges and opportunities they present. It further discusses the various types of nanoparticles, their mechanisms of action, and the future directions for overcoming existing barriers to their clinical application.
All articles published in the American Journal of Pharmacy and Pharmacology are licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows others to:
-
Share — copy and redistribute the material in any medium or format
-
Adapt — remix, transform, and build upon the material for any purpose, even commercially
Under the following terms:
-
Attribution — Appropriate credit must be given to the original author(s) and source, a link to the license must be provided, and any changes made must be indicated.
By submitting their work, authors agree to these licensing terms and retain copyright of their articles.